Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$71.2b

Lotus Pharmaceutical Balance Sheet Health

Financial Health criteria checks 5/6

Lotus Pharmaceutical has a total shareholder equity of NT$18.5B and total debt of NT$10.4B, which brings its debt-to-equity ratio to 56.1%. Its total assets and total liabilities are NT$34.6B and NT$16.2B respectively. Lotus Pharmaceutical's EBIT is NT$4.7B making its interest coverage ratio 9.5. It has cash and short-term investments of NT$2.9B.

Key information

56.1%

Debt to equity ratio

NT$10.37b

Debt

Interest coverage ratio9.5x
CashNT$2.86b
EquityNT$18.48b
Total liabilitiesNT$16.16b
Total assetsNT$34.64b

Recent financial health updates

Recent updates

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Financial Position Analysis

Short Term Liabilities: 1795's short term assets (NT$14.2B) exceed its short term liabilities (NT$6.6B).

Long Term Liabilities: 1795's short term assets (NT$14.2B) exceed its long term liabilities (NT$9.6B).


Debt to Equity History and Analysis

Debt Level: 1795's net debt to equity ratio (40.7%) is considered high.

Reducing Debt: 1795's debt to equity ratio has reduced from 87.9% to 56.1% over the past 5 years.

Debt Coverage: 1795's debt is well covered by operating cash flow (39.3%).

Interest Coverage: 1795's interest payments on its debt are well covered by EBIT (9.5x coverage).


Balance Sheet


Discover healthy companies